Cargando…
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma
To improve the outcomes of patients with the otherwise incurable hematologic malignancy of multiple myeloma (MM), a key paradigm includes initial treatment to establish disease control rapidly followed by maintenance therapy to ensure durability of response with manageable toxicity. However, patient...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Fondazione Ferrata Storti
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620581/ https://www.ncbi.nlm.nih.gov/pubmed/37608773 http://dx.doi.org/10.3324/haematol.2022.282624 |
_version_ | 1785130236782837760 |
---|---|
author | Richardson, Paul G. Durie, Brian G. Rosiñol, Laura Mateos, Maria-Victoria Dispenzieri, Angela Moreau, Philippe Kumar, Shaji Raje, Noopur Munshi, Nikhil Laubach, Jacob P. O’Gorman, Peter O’Donnell, Elizabeth Voorhees, Peter Facon, Thierry Bladé, Joan Lonial, Sagar Perrot, Aurore Anderson, Kenneth C. |
author_facet | Richardson, Paul G. Durie, Brian G. Rosiñol, Laura Mateos, Maria-Victoria Dispenzieri, Angela Moreau, Philippe Kumar, Shaji Raje, Noopur Munshi, Nikhil Laubach, Jacob P. O’Gorman, Peter O’Donnell, Elizabeth Voorhees, Peter Facon, Thierry Bladé, Joan Lonial, Sagar Perrot, Aurore Anderson, Kenneth C. |
author_sort | Richardson, Paul G. |
collection | PubMed |
description | To improve the outcomes of patients with the otherwise incurable hematologic malignancy of multiple myeloma (MM), a key paradigm includes initial treatment to establish disease control rapidly followed by maintenance therapy to ensure durability of response with manageable toxicity. However, patients’ prognosis worsens after relapse, and the disease burden and drug toxicities are generally more challenging with subsequent lines of therapy. It is therefore particularly important that patients with newly diagnosed multiple myeloma (NDMM) receive optimal frontline therapy. The combination of lenalidomide, bortezomib, and dexamethasone (RVd) has consistently demonstrated a tolerable safety profile with significant and clinically relevant benefit, including deep and durable responses with improved survival in patients with NDMM regardless of their transplant eligibility. Furthermore, comparative studies evaluating this triplet regimen against both doublet and other triplet regimens have established RVd as a standard of care in this setting based upon its remarkable and concordant efficacy. Given the breadth of clinical data, physician familiarity, inclusion in treatment guidelines, and the emerging potential of RVd-containing quadruplet regimens, RVd will likely continue as a key cornerstone of the treatment of NDMM, and its role will therefore likely continue to grow as a therapeutic backbone in the initial treatment of MM. |
format | Online Article Text |
id | pubmed-10620581 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Fondazione Ferrata Storti |
record_format | MEDLINE/PubMed |
spelling | pubmed-106205812023-11-03 Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma Richardson, Paul G. Durie, Brian G. Rosiñol, Laura Mateos, Maria-Victoria Dispenzieri, Angela Moreau, Philippe Kumar, Shaji Raje, Noopur Munshi, Nikhil Laubach, Jacob P. O’Gorman, Peter O’Donnell, Elizabeth Voorhees, Peter Facon, Thierry Bladé, Joan Lonial, Sagar Perrot, Aurore Anderson, Kenneth C. Haematologica Review Article To improve the outcomes of patients with the otherwise incurable hematologic malignancy of multiple myeloma (MM), a key paradigm includes initial treatment to establish disease control rapidly followed by maintenance therapy to ensure durability of response with manageable toxicity. However, patients’ prognosis worsens after relapse, and the disease burden and drug toxicities are generally more challenging with subsequent lines of therapy. It is therefore particularly important that patients with newly diagnosed multiple myeloma (NDMM) receive optimal frontline therapy. The combination of lenalidomide, bortezomib, and dexamethasone (RVd) has consistently demonstrated a tolerable safety profile with significant and clinically relevant benefit, including deep and durable responses with improved survival in patients with NDMM regardless of their transplant eligibility. Furthermore, comparative studies evaluating this triplet regimen against both doublet and other triplet regimens have established RVd as a standard of care in this setting based upon its remarkable and concordant efficacy. Given the breadth of clinical data, physician familiarity, inclusion in treatment guidelines, and the emerging potential of RVd-containing quadruplet regimens, RVd will likely continue as a key cornerstone of the treatment of NDMM, and its role will therefore likely continue to grow as a therapeutic backbone in the initial treatment of MM. Fondazione Ferrata Storti 2023-08-24 /pmc/articles/PMC10620581/ /pubmed/37608773 http://dx.doi.org/10.3324/haematol.2022.282624 Text en Copyright© 2023 Ferrata Storti Foundation https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Review Article Richardson, Paul G. Durie, Brian G. Rosiñol, Laura Mateos, Maria-Victoria Dispenzieri, Angela Moreau, Philippe Kumar, Shaji Raje, Noopur Munshi, Nikhil Laubach, Jacob P. O’Gorman, Peter O’Donnell, Elizabeth Voorhees, Peter Facon, Thierry Bladé, Joan Lonial, Sagar Perrot, Aurore Anderson, Kenneth C. Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma |
title | Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma |
title_full | Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma |
title_fullStr | Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma |
title_full_unstemmed | Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma |
title_short | Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma |
title_sort | clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620581/ https://www.ncbi.nlm.nih.gov/pubmed/37608773 http://dx.doi.org/10.3324/haematol.2022.282624 |
work_keys_str_mv | AT richardsonpaulg clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma AT duriebriang clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma AT rosinollaura clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma AT mateosmariavictoria clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma AT dispenzieriangela clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma AT moreauphilippe clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma AT kumarshaji clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma AT rajenoopur clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma AT munshinikhil clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma AT laubachjacobp clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma AT ogormanpeter clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma AT odonnellelizabeth clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma AT voorheespeter clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma AT faconthierry clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma AT bladejoan clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma AT lonialsagar clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma AT perrotaurore clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma AT andersonkennethc clinicalperspectivesontheoptimaluseoflenalidomideplusbortezomibanddexamethasoneforthetreatmentofnewlydiagnosedmultiplemyeloma |